SCHEMBL21114102

SCHEMBL21114102

Cn1nc2cc(Br)ccc2c1I

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.37
PDGFRA P16234 2/20 0.34
CDK5 Q00535 1/20 0.34
TYRO3 Q06418 1/20 0.34
CASP3 P42574 2/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
LMNA P02545 1/20 0.33
MPO P05164 1/20 0.33
MAPK8 P45983 1/20 0.33
HTT P42858 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1048915 0.85 CASP3 (0.40) CASP3TSHRMAPK1LMNAMPO
SCHEMBL15802261 0.79 PARP1 (0.40) HRH4LMNANPC1RAB9AALDH1A1
SCHEMBL2144329 0.79 PDGFRA (0.44) HRH4PDGFRACDK5TYRO3CASP3
SCHEMBL17610137 0.78 POLB (0.41) HRH4MPOALDH1A1MAPTALOX15
SCHEMBL17610160 0.78 KMT2A (0.34) PDGFRAMPOHTTALDH1A1MEN1
SCHEMBL17610140 0.78 HRH4 (0.40) HRH4PDGFRACDK5TYRO3CASP3
SCHEMBL15791888 0.75 KDM4C (0.42) LMNAHTTNPC1RAB9ASMN1; SMN2
SCHEMBL13106459 0.75 HTT (0.36) HRH4PDGFRACDK5TYRO3CASP3
SCHEMBL14737742 0.73 LRRK2 (0.36) SMN1; SMN2KDR
SCHEMBL4730929 0.73 CDK5 (0.41) PDGFRACDK5TYRO3CASP3MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115448881-A Heteroaryl compound, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2022-12-09 CN disclosed
WO-2019136314-A1 COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2019-07-11 WO disclosed
US-20190210973-A1 COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190210973-A1 COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS CFTR, SLC26A4, SERPINB1 HRH4 1091/4885PDGFRA 2874/4885CDK5 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.